2.
不同分期患者的EGFR突变状态与2年无疾病生存率、5年生存率的关系
the relationship of EGFR status and 2 year-DFS, 5 year-OS by stages
| Surgical stages | 2 year-DFS (n=218) | P | 5 year-OS (n=301) | P | EGFR-TKIs (n) |
| EGFR-TKIs:EGFR tyrosine kinase inhibitors. | |||||
| All stages | |||||
| EGFR (+) | 76.8% (86/112) | 0.252 | 67.7% (107/158) | 0.715 | 13 |
| EGFR (-) | 83.0% (88/106) | 65.7% (94/143) | 9 | ||
| Ⅰa, Ⅰb | |||||
| EGFR (+) | 89.9% (71/79) | 0.311 | 83.0% (78/94) | 0.728 | 3 |
| EGFR (-) | 94.4% (67/71) | 84.9% (73/86) | 5 | ||
| Ⅱa, Ⅱb | |||||
| EGFR (+) | 78.6% (11/14) | 0.999 | 68.0% (17/25) | 0.526 | 2 |
| EGFR (-) | 81.3% (13/16) | 59.1% (13/22) | 1 | ||
| Ⅲa | |||||
| EGFR (+) | 21.1% (4/19) | 0.295 | 30.8% (12/39) | 0.444 | 8 |
| EGFR (-) | 42.1% (8/19) | 22.9% (8/35) | 3 | ||